Literature DB >> 24626660

Acquired epidermodysplasia verruciformis in a renal transplant recipient--case report.

Alena Darwich Mendes1, Maraya de Jesus Semblano Bittencourt2, Emanuella Rosyane Duarte Moure3, Camila Maria D'Macêdo4, Igor Nagai Yamaki4, Dyandra Moreira de Araújo4.   

Abstract

A 24-year-old male patient, who underwent kidney transplant six years ago due to Lupus nephritis, for the last two years presented asymptomatic erythematous scaly plaques on the abdomen and areas exposed to light. Post-transplantation immunosuppressive medications included prednisone, mycophenolate sodium and sirolimus. The histopathologic features were typical for epidermodysplasia verruciformis. Epidermodysplasia verruciformis is a rare autosomal recessive genodermatosis with increased susceptibility to specific strains of cutaneous human papilloma virus. The term ''acquired epidermodysplasia verruciformis'' was recently introduced to the literature and describes epidermodysplasia verruciformis occurring in patients with impaired cell-mediated immunity. We report an additional case associated to immunosuppression after kidney transplantation.

Entities:  

Mesh:

Year:  2014        PMID: 24626660      PMCID: PMC3938366          DOI: 10.1590/abd1806-4841.20142803

Source DB:  PubMed          Journal:  An Bras Dermatol        ISSN: 0365-0596            Impact factor:   1.896


  9 in total

1.  Epidermodysplasia verruciformis-like lesions in a patient with systemic lupus erythematosus.

Authors:  Irene García-Río; Maria-Jose Garcia-F-Villalta; Esteban Daudén; Javier Fraga; Amaro García-Díez
Journal:  Acta Derm Venereol       Date:  2003       Impact factor: 4.437

2.  Epidermodysplasia verruciformis: clinical presentation with varied forms of lesions.

Authors:  Naiana Bittencourt de Sá; Marina Besen Guerini; Mariana Tremel Barbato; Gabriella Di Giunta; Daniel Holthausen Nunes
Journal:  An Bras Dermatol       Date:  2011 Jul-Aug       Impact factor: 1.896

3.  [Acquired epidermodysplasia verruciformis in a renal transplant recipient].

Authors:  S Gómez-Bernal; L Rodríguez-Pazos; M M Pereiro-Ferreirós; J Toribio
Journal:  Actas Dermosifiliogr       Date:  2011-02-02

Review 4.  Exploring treatment options in renal transplantation: the problems of chronic allograft dysfunction and drug-related nephrotoxicity.

Authors:  J M Campistol; J M Grinyó
Journal:  Transplantation       Date:  2001-06-15       Impact factor: 4.939

5.  Epidermodysplasia verruciformis-associated papillomavirus infection complicating human immunodeficiency virus disease.

Authors:  T G Berger; W S Sawchuk; C Leonardi; A Langenberg; J Tappero; P E Leboit
Journal:  Br J Dermatol       Date:  1991-01       Impact factor: 9.302

6.  A potentially oncogenic human papillomavirus (HPV-5) found in two renal allograft recipients.

Authors:  M Lutzner; O Croissant; M F Ducasse; H Kreis; J Crosnier; G Orth
Journal:  J Invest Dermatol       Date:  1980-10       Impact factor: 8.551

7.  Detection of human papillomavirus type 5 DNA in skin cancers of an immunosuppressed renal allograft recipient.

Authors:  M A Lutzner; G Orth; V Dutronquay; M F Ducasse; H Kreis; J Crosnier
Journal:  Lancet       Date:  1983-08-20       Impact factor: 79.321

8.  Epidermodysplasia verruciformis in a patient with Hodgkin's disease: characterization of a new papillomavirus type and interferon treatment.

Authors:  G Gross; K Ellinger; A Roussaki; P G Fuchs; H H Peter; H Pfister
Journal:  J Invest Dermatol       Date:  1988-07       Impact factor: 8.551

9.  Acquired epidermodysplasia verruciformis.

Authors:  Heather D Rogers; Jennifer L Macgregor; Kristin M Nord; Stephen Tyring; Peter Rady; Danielle E Engler; Marc E Grossman
Journal:  J Am Acad Dermatol       Date:  2009-02       Impact factor: 11.527

  9 in total
  1 in total

1.  Cornoid Lamella-Like Structures in HIV-Associated Epidermodysplasia Verruciformis: A Unique Histopathologic Finding.

Authors:  Courtney Champagne; Lindsey Moore; Ross Reule; Jonathan A Dyer; Peter Rady; Stephen K Tyring; Jeffrey P North
Journal:  Am J Dermatopathol       Date:  2015-12       Impact factor: 1.533

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.